

1102
3. (Amended) An enzymatic nucleic acid molecule of claim 2, wherein
said enzymatic nucleic acid molecule comprises any of the DNAzyme sequences
identified as SEQ ID NO: 1832-2779

12
4. (Amended) An enzymatic nucleic acid molecule which specifically
cleaves RNA derived from a TERT gene, wherein said enzymatic nucleic acid molecule
comprises sequences that are complementary to any of substrate sequences identified as
SEQ ID NO: 1-384 or 3164-5558.

13
5. (Amended) An antisense nucleic acid molecule comprising sequence
complementary to any of substrate sequences identified as SEQ ID NO: 1-384 or 3164-
5558.

25. (Amended) The enzymatic nucleic acid molecule of claim 1, wherein
said enzymatic nucleic acid molecule comprises any of sequences identified as SEQ ID
NO: 2780-3163.

13
26. (Amended) The enzymatic nucleic acid molecule of claim 1, wherein
said enzymatic nucleic acid molecule comprises any of sequences identified as SEQ ID
NO: 385-1453.

27. (Amended) The enzymatic nucleic acid molecule of claim 1, wherein
said enzymatic nucleic acid molecule comprises any of sequences identified as SEQ ID
NO: 1454-1831.

28. (Amended) The enzymatic nucleic acid molecule of claim 1, wherein
said enzymatic nucleic acid molecule comprises any of sequences identified as SEQ ID
NO: 5559-5568, 4332, 4471, or 4594

THE RESTRICTION REQUIREMENT

The Office Action alleges that the claims of the instant invention are subject to a restriction because they are related as product and process of use. Specifically, it is asserted that the claims fall under two distinct groups: Group I, claims 1-15 and 25-30 drawn to antisense and enzymatic nucleic acid molecules; and Group II, claims 16-24 drawn to methods of inhibiting telomerase enzyme activity comprising the nucleic acid molecules of Group I. Applicants elect Group I, claims 1-15 and 25-30, with traverse.

The Office further alleges that the sequences listed in claims 1 and 3-5 are subject to further restriction, pursuant to 35 U.S.C. 121 and 37 C.F.R. 1.141. The Office quotes to M.P.E.P. § 2434, "the Commissioner has partially waived the requirements of 37 C.F.R. 1.141 and will permit a reasonable number of such nucleotide sequences to be claimed in a single invention. Under this policy, in most cases, up to 10 independent and distinct nucleotide sequences will be examined in a single application without restriction. Those sequences which are patently indistinct from the sequences selected by the applicant will also be examined." Thus, Applicants are required to elect up to 10 claimed sequences from claims 1, 3-5, and 25-28.

Applicants elect SEQ ID NOS: 1832-1841 (to enzymatic nucleic acid molecules), and SEQ ID NOS: 4611-4620 (corresponding substrate sequences), with traverse.

REMARKS

I. Support for Claim amendments

The Office objects to claims 1, 3-5, and 25-28, asserted as not complying with 37 C.F.R. §§ 1.821-1.825, and M.P.E.P. § 2173.05(s) because of language that refers to Tables found in the body of the specification. Applicants have amended the claims as noted above, in order to obviate the objection. The amendments are not made to overcome prior art and serve merely to clarify the language of the claims. The amendments do not constitute new matter and are supported in the specification, for example, in Tables III-VII.